Crispr Therapeut - CRSP STOCK NEWS

CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals reported promising data for CTX001, a CRISPR/Cas9 gene-editing therapy, at the ASH Meeting. In beta thalassemia, all seven patients were transfusion independent after 3 to 18 months post-infusion. For sickle cell disease, three patients experienced no vaso-occlusive crises within 3 to 15 months. The New England Journal of Medicine published a peer-reviewed article detailing these findings. CTX001 is being advanced through Phase 1/2 trials and has received several FDA designations to expedite its development.

CRISPR Therapeutics and Vertex Pharmaceuticals will host an investor webcast on December 9, 2020, at 8:00 a.m. ET. The event will focus on clinical data from ongoing Phase 1/2 trials of CTX001, a gene-editing therapy for sickle cell disease and beta thalassemia, which will be presented at the ASH Meeting. Notable speakers include representatives from both companies and Dr. Haydar Frangoul. The webcast will be accessible via the companies' websites, and an archived version will be available for 30 days.

The collaboration aims to develop gene-based treatments using CRISPR/Cas9 technology.

CRISPR Therapeutics (Nasdaq: CRSP) announced participation at the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2, 2020, at 9:30 a.m. ET. Senior management will represent the company, which specializes in gene-based medicines for severe diseases using its CRISPR/Cas9 technology. A live webcast will be available on the company’s website, with a replay accessible for 14 days post-event. CRISPR Therapeutics holds collaborations with Bayer, Vertex Pharmaceuticals, and ViaCyte, and operates headquarters in Zug, Switzerland, and a U.S. subsidiary in Cambridge, Massachusetts.

CRISPR Therapeutics (Nasdaq: CRSP) has announced its participation in the Jefferies London Healthcare Conference on November 19, 2020, at 12:00 p.m. ET. The management team will engage in a virtual event, with a live webcast accessible on the company’s website under 'Events & Presentations'. A replay will be available for 14 days post-presentation. Known for its innovative CRISPR/Cas9 gene editing technology, CRISPR Therapeutics aims to develop transformative medicines for serious diseases, collaborating with partners like Bayer and Vertex Pharmaceuticals.

CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals announced the acceptance of data from two ongoing Phase 1/2 clinical trials of CTX001, a CRISPR/Cas9 gene-editing therapy for severe hemoglobinopathies, for oral presentation at the annual ASH Meeting in December 2020. The trials focus on transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). CTX001 aims to provide a one-time curative therapy by elevating fetal hemoglobin levels. The therapy has received multiple FDA designations, emphasizing its potential in treating these serious conditions.

CRISPR Therapeutics reported significant advancements in its clinical trials and financial results for Q3 2020. The company achieved positive results from its Phase 1 CARBON trial for CTX110, showing a 50% complete response rate. It received Rare Pediatric Disease designation for CTX001 targeting sickle cell disease and Orphan Drug Designation for CTX120. Financially, cash increased to $1.4 billion, but total collaboration revenue dropped to $0.1 million from $211.9 million year-over-year, with a net loss of $92.4 million.

CRISPR Therapeutics announced positive results from the Phase 1 CARBON trial evaluating CTX110, an allogeneic CAR-T cell therapy for CD19+ B-cell malignancies. As of the September 28, 2020 data cutoff, a 50% complete response rate was observed at Dose Level 3, with both responders maintaining their status. The therapy exhibited a favorable safety profile, with no dose-limiting toxicities reported. Management expressed confidence in the potential of CTX110 for broader patient access. The trial aims to assess multiple dose levels and the company is working towards further data releases in the coming year.

CRISPR Therapeutics (Nasdaq: CRSP) celebrates the recognition of co-founder Professor Emmanuelle Charpentier, awarded the 2020 Nobel Prize in Chemistry for her contributions to the CRISPR/Cas9 technology. This honor reflects the significant impact of CRISPR research on gene-based therapies for serious diseases. CRISPR Therapeutics, leveraging this technology, aims to develop transformative medicines across various disease areas, notably in oncology and rare diseases. The company remains committed to advancing gene editing innovations amid the growing importance of genetic research.

CRISPR Therapeutics (Nasdaq: CRSP) announced its senior management will participate in two upcoming investor conferences in August 2020. The William Blair Biotech Focus Conference is scheduled for August 6 at 1:00 p.m. ET, while the Canaccord Genuity 40th Annual Growth Conference will take place on August 13 at 2:30 p.m. ET. Live webcasts of these events will be available on the company's website, with archives accessible for 14 days post-presentation. CRISPR Therapeutics focuses on developing gene-based medicines utilizing its innovative CRISPR/Cas9 platform.